CU20160078A7 - DERIVATIVES OF N- (3- (6-AMINOPIRIDIN-4-IL) PHENYL) BENZAMIDA AS BTK INHIBITORS - Google Patents
DERIVATIVES OF N- (3- (6-AMINOPIRIDIN-4-IL) PHENYL) BENZAMIDA AS BTK INHIBITORSInfo
- Publication number
- CU20160078A7 CU20160078A7 CUP2016000078A CU20160078A CU20160078A7 CU 20160078 A7 CU20160078 A7 CU 20160078A7 CU P2016000078 A CUP2016000078 A CU P2016000078A CU 20160078 A CU20160078 A CU 20160078A CU 20160078 A7 CU20160078 A7 CU 20160078A7
- Authority
- CU
- Cuba
- Prior art keywords
- derivatives
- aminopiridin
- benzamida
- phenyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención describe nuevos derivados de pirimidina de fórmula (I) espacio para fórmula que parecen interactuar con Ia tirosina quinasa de Bruton (Btk). De acuerdo con lo anterior, los derivados novedosos de amino pirimidina pueden ser efectivos en el tratamiento de trastornos autoinmunes, enfermedades inflamatorias, enfermedades alérgicas, enfermedades de las vias aéreas, tales como asma y enfermedad pulmonar obstructiva crónica (EPOC), rechazo de trasplantes, cánceres, por ejemplo tumores sólidos o de origen hematopoyético.The present invention describes new pyrimidine derivatives of formula (I) space for formula that seem to interact with Bruton tyrosine kinase (Btk). In accordance with the foregoing, novel amino pyrimidine derivatives can be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers, for example solid or hematopoietic tumors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13195081 | 2013-11-29 | ||
PCT/IB2014/066422 WO2015079417A1 (en) | 2013-11-29 | 2014-11-28 | Novel amino pyrimidine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20160078A7 true CU20160078A7 (en) | 2016-09-30 |
CU24384B1 CU24384B1 (en) | 2019-03-04 |
Family
ID=49674216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2016000078A CU24384B1 (en) | 2013-11-29 | 2014-11-28 | DERIVATIVES OF N- (3- (6-AMINOPIRIDIN-4-IL) PHENYL) BENZAMIDA AS BTK INHIBITORS |
Country Status (43)
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI654206B (en) | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
IL293603B2 (en) | 2014-04-07 | 2024-03-01 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
CN112481283A (en) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | Treatment of cancer using CD33 chimeric antigen receptor |
JP2017528433A (en) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | Low immunoenhancing dose of mTOR inhibitor and CAR combination |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CN106687483B (en) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptors |
US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
DK3194443T3 (en) | 2014-09-17 | 2021-09-27 | Novartis Ag | TARGETING OF CYTOTOXIC CELLS WITH CHIMARY RECEPTORS IN CONNECTION WITH ADOPTIVE IMMUNTERAPHY |
SG11201702895SA (en) | 2014-10-08 | 2017-05-30 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
CU20170052A7 (en) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | ANTIBODY MOLECULES THAT JOIN PD-L1 |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
EP3280795B1 (en) * | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
SI3280729T1 (en) | 2015-04-08 | 2022-09-30 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
SI3317301T1 (en) | 2015-07-29 | 2021-10-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
JP7082055B2 (en) | 2015-12-22 | 2022-06-07 | ノバルティス アーゲー | Antibodies to Mesothelin Chimeric Antigen Receptor (CAR) and PD-L1 Inhibitors for Combined Use in Anticancer Treatment |
EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
KR102565885B1 (en) | 2016-07-20 | 2023-08-09 | 유니버시티 오브 유타 리서치 파운데이션 | CD229 CAR T Cells and Methods of Using The Same |
AR110676A1 (en) | 2016-10-07 | 2019-04-24 | Novartis Ag | TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS |
US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
JP2020526194A (en) | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | Mouse model for assessing toxicity associated with immunotherapeutic agents |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
KR20200116077A (en) | 2017-11-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | Chimeric antigen receptor and coding polynucleotide specific for B cell maturation antigen |
CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
AR113796A1 (en) * | 2017-11-06 | 2020-06-10 | Lilly Co Eli | BRUTON TYROSINE KINASE (BTK) INHIBITING COMPOUNDS |
CN111989106A (en) | 2017-12-01 | 2020-11-24 | 朱诺治疗学股份有限公司 | Methods of administering and regulating genetically engineered cells |
CN108069911A (en) * | 2017-12-14 | 2018-05-25 | 中国药科大学 | 6- amino -2- phenyl pyrimidine classes compound, preparation method and medical usage |
EP3724225A1 (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
CN112424207B (en) | 2018-07-25 | 2024-03-19 | 诺华股份有限公司 | NLRP3 inflammatory corpuscle inhibitor |
WO2020092848A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
WO2020092854A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
JP2022513062A (en) | 2018-11-16 | 2022-02-07 | ジュノー セラピューティクス インコーポレイテッド | Methods of Dosing Manipulated T Cells to Treat B-Cell Malignancies |
JP2022513685A (en) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | Methods for Treatment with Adoptive Cell Therapy |
PE20212198A1 (en) | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | ANTIBODIES AND CHIMERIC RECEPTORS OF SPECIFIC ANTIGENS TO ORPHAN RECEPTOR 1, RECEPTOR TYROSINE KINASE TYPE (ROR1) |
AR119731A1 (en) | 2019-05-17 | 2022-01-05 | Novartis Ag | NLRP3 INFLAMASOME INHIBITORS |
JP2022534216A (en) * | 2019-05-23 | 2022-07-28 | ノバルティス アーゲー | Crystal forms of BTK inhibitors |
CA3138081A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor |
BR112021023110A2 (en) * | 2019-05-23 | 2022-04-12 | Novartis Ag | Methods of treating sjögren's syndrome with the use of a bruton tyrosine kinase inhibitor |
WO2020234780A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating asthma using a bruton's tyrosine kinase inhibitor |
EP4081514A1 (en) * | 2019-12-23 | 2022-11-02 | Biogen MA Inc. | Btk inhibitors |
KR20230009386A (en) | 2020-04-10 | 2023-01-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods and uses for cell therapy engineered with chimeric antigen receptors targeting B-cell maturation antigens |
CN116209444A (en) * | 2020-08-14 | 2023-06-02 | 苏州晶云药物科技股份有限公司 | Crystal forms of benzamide compounds and preparation method thereof |
WO2022034529A1 (en) | 2020-08-14 | 2022-02-17 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
KR20230134560A (en) | 2021-01-26 | 2023-09-21 | 노파르티스 아게 | pharmaceutical composition |
EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
IL310975A (en) | 2021-09-03 | 2024-04-01 | Novartis Ag | Lou064 for treating multiple sclerosis |
JP2024504267A (en) | 2021-12-14 | 2024-01-31 | ノバルティス アーゲー | Treatment method using LOU064 |
TW202342048A (en) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | Methods of treating hidradenitis suppurativa using lou064 |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024069507A1 (en) | 2022-09-30 | 2024-04-04 | Novartis Ag | Synthesis methods and intermediates for the production of remibrutinib |
CN117024354B (en) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | Preparation method of Rui Mi Buti Ni |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
AU2002236692A1 (en) | 2000-10-23 | 2002-05-21 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use |
KR20080014934A (en) | 2000-11-07 | 2008-02-14 | 노파르티스 아게 | Indolylmaleimide derivatives as protein kinase c inhibitors |
AR036053A1 (en) | 2001-06-15 | 2004-08-04 | Versicor Inc | N-FORMIL-HYDROXYLAMINE COMPOUNDS, A PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS |
AR039209A1 (en) | 2002-04-03 | 2005-02-09 | Novartis Ag | INDOLILMALEIMIDA DERIVATIVES |
EP2322202A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune diseases |
AU2003297740B2 (en) | 2002-12-09 | 2008-09-11 | The Board Of Regents Of The University Of Texas System | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) |
JP2007524596A (en) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | Co-crystal pharmaceutical composition |
EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
CA2524048C (en) | 2003-05-19 | 2013-06-25 | Irm Llc | Immunosuppressant compounds and compositions |
CA2545427C (en) | 2004-01-12 | 2012-08-21 | Cytopia Research Pty Ltd | Selective kinase inhibitors |
BRPI0608252A2 (en) | 2005-03-10 | 2010-04-06 | Cgi Pharmaceuticals Inc | chemical entities, pharmaceutical compositions comprising them, methods using said chemical entities and use of said chemical entities |
AR063946A1 (en) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | CERTAIN REPLACED PIRIMIDINS, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. |
US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
EP2081435B1 (en) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
SI2134374T1 (en) | 2007-03-14 | 2014-03-31 | Bionsil S.R.L. In Liquidazione | Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours |
ES2554615T3 (en) | 2008-05-06 | 2015-12-22 | Gilead Connecticut, Inc. | Substituted amides, method of preparation and use as Btk inhibitors |
PE20110164A1 (en) | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | NEW PHENYLpyRAZINONES AS KINASE INHIBITORS |
EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US20100261776A1 (en) | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
ES2513915T3 (en) | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Bruton Tyrosine Kinase Inhibitors |
US8853193B2 (en) * | 2010-02-26 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
UY33241A (en) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?. |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
CN103889962B (en) | 2011-04-01 | 2017-05-03 | 犹他大学研究基金会 | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors |
DK2710007T3 (en) | 2011-05-17 | 2020-01-27 | Principia Biopharma Inc | kinase inhibitors |
HUE059230T2 (en) | 2011-06-10 | 2022-10-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
BR112013033534A2 (en) | 2011-06-28 | 2017-02-07 | Pharmacyclics Inc | methods and compositions for inhibiting bone resorption |
CN103732596B (en) | 2011-07-08 | 2016-06-01 | 诺华股份有限公司 | Pyrrolopyrimidine derivatives |
EP3778896A1 (en) | 2011-08-09 | 2021-02-17 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells |
KR20230109775A (en) | 2011-10-19 | 2023-07-20 | 파마싸이클릭스 엘엘씨 | Use of inhibitors of bruton's tyrosine kinase (btk) |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
RU2014126750A (en) | 2011-12-09 | 2016-01-27 | Ф. Хоффманн-Ля Рош Аг | BRUTON TYROSINKINASE INHIBITORS |
CN104169260A (en) | 2012-03-09 | 2014-11-26 | 卡尔那生物科学株式会社 | Novel triazone derivative |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
JP6182593B2 (en) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | Substituted heterobicyclic compounds, compositions and medicaments and uses thereof |
US9133134B2 (en) | 2012-05-16 | 2015-09-15 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
BR112015002590A2 (en) | 2012-08-10 | 2019-08-06 | Boehringer Ingelheim Int | heteroaromatic compounds as bruton tyrosine kinase (btk) inhibitors |
EP3680238A1 (en) | 2012-10-04 | 2020-07-15 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2014
- 2014-11-13 US US14/540,140 patent/US9512084B2/en active Active
- 2014-11-27 JO JOP/2014/0341A patent/JO3314B1/en active
- 2014-11-27 AR ARP140104439A patent/AR098549A1/en active IP Right Grant
- 2014-11-27 UY UY0001035858A patent/UY35858A/en active IP Right Grant
- 2014-11-28 LT LTEP17191467.4T patent/LT3299368T/en unknown
- 2014-11-28 MA MA39055A patent/MA39055B1/en unknown
- 2014-11-28 DK DK20158961.1T patent/DK3689865T3/en active
- 2014-11-28 EP EP23161775.4A patent/EP4219478A1/en active Pending
- 2014-11-28 KR KR1020227009823A patent/KR102421388B1/en active IP Right Grant
- 2014-11-28 MY MYPI2020002915A patent/MY191381A/en unknown
- 2014-11-28 CA CA2926908A patent/CA2926908C/en active Active
- 2014-11-28 BR BR112016010397-1A patent/BR112016010397B1/en active IP Right Grant
- 2014-11-28 UA UAA201603623A patent/UA117256C2/en unknown
- 2014-11-28 CU CU2016000078A patent/CU24384B1/en unknown
- 2014-11-28 TW TW103141506A patent/TWI652261B/en active
- 2014-11-28 TN TN2016000128A patent/TN2016000128A1/en unknown
- 2014-11-28 EP EP20158961.1A patent/EP3689865B1/en active Active
- 2014-11-28 JP JP2016535053A patent/JP6342495B2/en active Active
- 2014-11-28 EP EP14821285.5A patent/EP3074386B1/en active Active
- 2014-11-28 ES ES20158961T patent/ES2947770T3/en active Active
- 2014-11-28 PT PT201589611T patent/PT3689865T/en unknown
- 2014-11-28 DK DK17191467.4T patent/DK3299368T3/en active
- 2014-11-28 AP AP2016009158A patent/AP2016009158A0/en unknown
- 2014-11-28 HU HUE14821285A patent/HUE037588T2/en unknown
- 2014-11-28 ES ES17191467T patent/ES2791525T3/en active Active
- 2014-11-28 MY MYPI2016701223A patent/MY179059A/en unknown
- 2014-11-28 PL PL17191467T patent/PL3299368T3/en unknown
- 2014-11-28 CN CN201480058515.5A patent/CN105683181B/en active Active
- 2014-11-28 HU HUE17191467A patent/HUE049794T2/en unknown
- 2014-11-28 RS RS20230437A patent/RS64275B1/en unknown
- 2014-11-28 NZ NZ718835A patent/NZ718835A/en unknown
- 2014-11-28 KR KR1020167013830A patent/KR102380539B1/en active IP Right Grant
- 2014-11-28 EA EA201691125A patent/EA031218B1/en not_active IP Right Cessation
- 2014-11-28 PE PE2016000683A patent/PE20160869A1/en unknown
- 2014-11-28 LT LTEP14821285.5T patent/LT3074386T/en unknown
- 2014-11-28 DK DK14821285.5T patent/DK3074386T3/en active
- 2014-11-28 HU HUE20158961A patent/HUE062248T2/en unknown
- 2014-11-28 CN CN201910288376.XA patent/CN110172056B/en active Active
- 2014-11-28 SI SI201432031T patent/SI3689865T1/en unknown
- 2014-11-28 ES ES14821285.5T patent/ES2655527T3/en active Active
- 2014-11-28 SI SI201430536T patent/SI3074386T1/en unknown
- 2014-11-28 AU AU2014356069A patent/AU2014356069B2/en active Active
- 2014-11-28 RS RS20171206A patent/RS56657B1/en unknown
- 2014-11-28 PL PL14821285T patent/PL3074386T3/en unknown
- 2014-11-28 WO PCT/IB2014/066422 patent/WO2015079417A1/en active Application Filing
- 2014-11-28 NO NO14821285A patent/NO3074386T3/no unknown
- 2014-11-28 MX MX2016006908A patent/MX367911B/en active IP Right Grant
- 2014-11-28 FI FIEP20158961.1T patent/FI3689865T3/en active
- 2014-11-28 PL PL20158961.1T patent/PL3689865T3/en unknown
- 2014-11-28 HR HRP20230585TT patent/HRP20230585T1/en unknown
- 2014-11-28 PT PT148212855T patent/PT3074386T/en unknown
- 2014-11-28 LT LTEP20158961.1T patent/LT3689865T/en unknown
- 2014-11-28 PT PT171914674T patent/PT3299368T/en unknown
- 2014-11-28 SI SI201431570T patent/SI3299368T1/en unknown
- 2014-11-28 RS RS20200550A patent/RS60251B1/en unknown
- 2014-11-28 EP EP17191467.4A patent/EP3299368B1/en active Active
-
2016
- 2016-04-05 ZA ZA2016/02275A patent/ZA201602275B/en unknown
- 2016-04-06 IL IL244943A patent/IL244943B/en active IP Right Grant
- 2016-04-21 US US15/135,296 patent/US20160235746A1/en not_active Abandoned
- 2016-04-28 PH PH12016500791A patent/PH12016500791A1/en unknown
- 2016-05-03 CL CL2016001055A patent/CL2016001055A1/en unknown
- 2016-05-27 CR CR20160244A patent/CR20160244A/en unknown
- 2016-05-27 SV SV2016005206A patent/SV2016005206A/en unknown
- 2016-06-20 EC ECIEPI201654826A patent/ECSP16054826A/en unknown
- 2016-10-06 HK HK16111636.9A patent/HK1223368A1/en unknown
-
2017
- 2017-12-22 CY CY20171101345T patent/CY1119705T1/en unknown
- 2017-12-27 HR HRP20171999TT patent/HRP20171999T1/en unknown
-
2018
- 2018-05-08 US US15/974,190 patent/US10457647B2/en active Active
- 2018-05-16 JP JP2018094772A patent/JP6667573B2/en active Active
- 2018-09-10 HK HK18111597.4A patent/HK1252317A1/en unknown
-
2019
- 2019-09-16 US US16/571,405 patent/US11180460B2/en active Active
-
2020
- 2020-05-12 HR HRP20200775TT patent/HRP20200775T1/en unknown
- 2020-05-25 CY CY20201100478T patent/CY1122924T1/en unknown
-
2021
- 2021-10-22 US US17/508,054 patent/US11673868B2/en active Active
-
2023
- 2023-05-01 US US18/309,948 patent/US20230312483A1/en active Pending
- 2023-06-27 CY CY20231100301T patent/CY1126056T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20160078A7 (en) | DERIVATIVES OF N- (3- (6-AMINOPIRIDIN-4-IL) PHENYL) BENZAMIDA AS BTK INHIBITORS | |
EA201490229A1 (en) | NEW PYRROPHYRIMIDINE DERIVATIVES | |
CY1121763T1 (en) | DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | |
CU20160167A7 (en) | COMPOUNDS OF PIRAZOLOPIRIDINAS AND PIRAZOLOPIRIMIDINAS USEFUL IN THE TREATMENT OF ALLERGIC AND RESPIRATORY CONDITIONS | |
BR112017011798A2 (en) | 4,6-substituted-pyrazolo [1,5-a] pyrazines as janus kinase inhibitors | |
CL2016001543A1 (en) | Isocromen derivatives as inhibitors of phosphoinositido-3 kinases. | |
BR112015009942A2 (en) | tricyclic fused thiophene derivatives as jak inhibitors | |
ECSP14013282A (en) | 1-PIRAZOLIL-3- (4 - ((2-ANILINOPIRIMIDIN-4-IL) OXI) NAFTALEN-1-IL) UREAS AS INHIBITORS OF PROTEIN KINASES ACTIVATED BY MITOGEN P38 | |
EA201391033A1 (en) | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | |
GT201500218A (en) | COMPOUND | |
UY33884A (en) | INHIBITION OF IL17 AND IFN-GAMMA FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATIONS | |
DOP2015000299A (en) | DERIVATIVES OF PRODUCTION OF SUBSTITUTED TRIAZOLPIRIDINES | |
CL2011000424A1 (en) | Compounds derived from (phenyl) -amide of 7- (heteroaryl methyl) -1h-indole-2-carboxylic acid, p38 map kinase inhibitors; pharmaceutical composition; procedure for preparing said composition; and use of the compounds in the treatment of airway diseases such as epoc and asthma. | |
MX2016001747A (en) | Diphenylox. | |
ECSP15021681A (en) | FUSED TRICYCLIC DERIVATIVES OF THIOPHENE AS JAK INHIBITORS | |
CU20150136A7 (en) | DERIVATIVES OF OXOPIRIDONE REPLACED EMPLOYEES IN CARDIOVASCULAR DISORDERS | |
UA110978C2 (en) | Azetidinylphenyl, pyridyl or pyrazinylcarboxamide derivatives as JAK inhibitors |